GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Kangmei Pharmaceutical Co 600518.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

1.33

-0.75%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥5.25bn

FY2016FY2025

Net income

CN¥10.3m

FY2016FY2025

Free cash flow

−CN¥105.7m

FY2016FY2025

Shareholders' equity

CN¥7.29bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥5.25bnCN¥5.19bnCN¥4.87bnCN¥4.18bnCN¥4.15bnCN¥5.41bnCN¥11.45bnCN¥17.07bnCN¥17.58bnCN¥21.64bn
Gross profitCN¥1.05bnCN¥653.4mCN¥728.9mCN¥431.1mCN¥91.5m−CN¥23.63bnCN¥948.0mCN¥5.38bnCN¥6.76bnCN¥6.45bn
Research and developmentCN¥45.3mCN¥51.5mCN¥45.6mCN¥25.4mCN¥9.3mCN¥11.4mCN¥110.1mCN¥142.3mCN¥141.4mCN¥124.6m
Operating incomeCN¥111.7m−CN¥24.8mCN¥86.7m−CN¥1.78bnCN¥10.11bn−CN¥30.49bn−CN¥3.87bnCN¥686.9mCN¥2.89bnCN¥3.96bn
Net incomeCN¥10.3mCN¥8.6mCN¥102.5m−CN¥2.69bnCN¥7.92bn−CN¥31.08bn−CN¥4.66bnCN¥374.5mCN¥2.15bnCN¥3.34bn
Diluted earnings per share0.000.000.01-0.190.69-6.30-0.890.080.430.66

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥13.22bnCN¥13.80bnCN¥14.28bnCN¥15.11bnCN¥16.05bnCN¥33.33bnCN¥64.59bnCN¥73.14bnCN¥65.29bnCN¥54.82bn
Cash and short-term investments—CN¥977.9mCN¥1.06bnCN¥1.51bnCN¥2.42bnCN¥552.3mCN¥507.1mCN¥1.84bnCN¥4.21bnCN¥27.33bn
Total liabilitiesCN¥5.89bnCN¥6.59bnCN¥7.20bnCN¥8.18bnCN¥6.09bnCN¥43.74bnCN¥43.94bnCN¥47.03bnCN¥36.78bnCN¥25.44bn
Debt—CN¥110.8mCN¥214.3mCN¥263.9mCN¥205.3mCN¥31.08bnCN¥32.93bnCN¥29.04bnCN¥22.18bnCN¥13.14bn
Shareholders' equityCN¥7.29bnCN¥7.17bnCN¥7.05bnCN¥6.95bnCN¥9.93bn−CN¥10.54bnCN¥20.52bnCN¥25.58bnCN¥28.41bnCN¥29.12bn
Shares outstanding13,829m13,864m12,117m13,864m11,486m4,936m5,233m4,931m4,997m5,035m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥111.3m−CN¥427.6m−CN¥317.5m−CN¥750.0mCN¥214.2mCN¥1.03bnCN¥2.88bnCN¥305.6m−CN¥4.84bnCN¥1.60bn
Capital spending−CN¥217.1m−CN¥61.7m−CN¥99.7m−CN¥48.1m−CN¥171.6m−CN¥301.7m−CN¥473.2m−CN¥4.59bn−CN¥2.15bn−CN¥1.57bn
Free cash flow−CN¥105.7m−CN¥489.3m−CN¥417.3m−CN¥798.1mCN¥42.6mCN¥729.7mCN¥2.41bn−CN¥4.29bn−CN¥6.99bnCN¥35.8m
Dividends paid—−CN¥750,000—−CN¥897,000−CN¥13.8m−CN¥1.03bn−CN¥2.55bn−CN¥3.02bn−CN¥2.22bn−CN¥1.93bn

Latest quarters

By quarter end

Sept 2026Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024
RevenueCN¥1.24bnCN¥1.21bnCN¥1.08bnCN¥1.29bnCN¥1.37bnCN¥1.28bnCN¥1.30bnCN¥1.32bn
Gross profitCN¥269.3mCN¥249.6mCN¥238.3mCN¥294.1mCN¥255.3mCN¥249.2mCN¥235.5mCN¥104.9m
Operating incomeCN¥19.3m−CN¥24.8m−CN¥10.9mCN¥147.2m−CN¥36.7mCN¥16.5mCN¥13.1mCN¥16.0m
Net incomeCN¥57.4mCN¥52.6m−CN¥16.6m−CN¥2.8m−CN¥3.8mCN¥8.4mCN¥8.5mCN¥3.6m
Diluted earnings per share0.000.00-0.00-0.00-0.000.000.000.00
Cash from operations————CN¥219.0mCN¥19.0m−CN¥101.0m−CN¥77.0m
Capital spending−CN¥17.0m−CN¥10.0m−CN¥15.0m−CN¥142.0m−CN¥48.0m−CN¥18.0m−CN¥7.0m−CN¥24.0m
Free cash flow————CN¥171.0mCN¥1.0m−CN¥108.0m−CN¥101.0m
Total assetsCN¥12.91bnCN¥13.07bnCN¥13.31bnCN¥13.22bnCN¥13.68bnCN¥13.64bnCN¥13.71bnCN¥13.80bn
Cash and short-term investments————CN¥1.18bnCN¥902.7mCN¥894.2mCN¥977.9m
Debt————CN¥114.8mCN¥20.1mCN¥33.0mCN¥15.8m
Shareholders' equityCN¥7.38bnCN¥7.33bnCN¥7.27bnCN¥7.29bnCN¥7.19bnCN¥7.19bnCN¥7.18bnCN¥7.17bn

Financial ratios

Data as of 23 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin20.0%12.6%15.0%10.3%2.2%-436.7%—
Operating margin1.0%-8.0%1.8%-24.9%-73.4%-495.1%—
Net margin0.2%0.2%2.1%-64.3%190.7%-574.4%—
Return on equity0.1%0.1%1.5%-38.7%79.8%295.0%—
Return on assets0.1%0.1%0.7%-17.8%49.3%-93.3%—
Free cash flow yield1.8%-2.0%-1.3%-3.7%2.5%20.0%—
Revenue growth1.2%6.5%16.6%0.7%-23.3%-52.7%—
Earnings growth20.5%-91.6%-103.8%-134.0%-125.5%567.0%—
Current ratio1.26x1.17x1.46x1.36x1.67x0.80x—
Debt to equity—0.00x0.00x0.01x0.01x-2.06x1.75x
Equity ratio55.1%52.0%49.4%46.0%61.8%-31.6%—
Interest coverage2.84x-18.45x1.50x-12.87x-2.98x-12.21x—
R&D as a share of sales0.9%1.0%0.9%0.6%0.2%0.2%—
Buybacks as a share of market value0.3%-14.4%12.6%-20.7%-132.7%5.7%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue7.9%-0.6%-11.6%
Operating income——-28.5%
Net income——-42.8%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin16.3%14.7%-71.2%3.5%
Operating margin0.8%-8.2%-75.7%-13.2%
Net margin0.2%-13.2%-88.6%-19.0%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings——219.8-11.34.5-0.4-3.9113.948.625.1
Price to sales5.06.34.67.38.62.31.62.56.03.9

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 28 Aug 2019.

FY2019FY2018FY2017FY2016FY2015FY2014FY2013FY2012
Paid in the year0.0240.2350.2050.190.320.130.100.025
  • 1.065-for-1 split · 15 Dec 2021
  • 2-for-1 split · 22 Apr 2009
  • 3-for-2 split · 4 Mar 2008
  • 2-for-1 split · 8 May 2007
  • 3-for-2 split · 18 May 2006
  • 1-to-1 reverse split · 25 Oct 2005

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.